Laxmi Organic Industries Limited has informed the Exchange about Transcript
LXCHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Laxmi Organic Industries reported FY25 with 11% volume growth and EBITDA margin of 9.4% (up from 9%), while PAT margin dipped to 3.8% from 4.22% on higher sea freight costs (up ~60% YoY) and finance costs from recent capex. Q4 saw gross margin compress to 34.6% from 35.6%, with a one-time INR 68 million loss on asset sale and adjusted EBITDA of 9.3% vs 10.2%; the decline is largely a tough comparison as last year had an unplanned supplier shutdown. Management announced an LOI with Hitachi Energy to enter the power transmission segment, leveraging the Lote fluorine complex where commercial sales began in Q4. The Dahej project (Indra Dhanush) received environmental clearance and remains on track, and management reiterated FY28 targets of 20% ROCE, 2x revenue, specialty EBITDA in the 20-25% range, and diketene global top 3 status. CFO outlined INR 1,100 crore total capex (mostly in 1H FY26), peak term loans of INR 300-350 crore repayable by FY27-28, no equity dilution, and a current debt-equity of 0.23-0.30 at peak.
Mixed near-term but positive structural setup. Specialty segment is a clear strength at 23% EBITDA margins and is gaining new growth avenues (Hitachi LOI, fluoro intermediates, Dahej diketene expansion), while the essentials business is at the bottom of the cycle at 3% EBITDA margins, weighing on consolidated performance. Watch for Dahej commissioning in H2 FY26, Hitachi contract finalization, and signs of an essentials cycle turn as key catalysts; near-term, sea freight pressure and a minor specialty product regulatory phaseout cap upside.